Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Open accessThe DOI matches its Crossref record; 273 of the 276 references it cites were found in a registry or an index.
Abstract
We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinopathy in older adults, with or without coexisting hippocampal sclerosis pathology. LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome that mimicked Alzheimer's-type dementia in retrospective autopsy studies. LATE is distinguished from frontotemporal lobar degeneration with TDP-43 pathology based on its epidemiology (LATE generally affects older subjects), and relatively restricted neuroanatomical distribution of TDP-43 proteinopathy. In community-based autopsy cohorts, ∼25% of brains had sufficient burden of LATE-NC to be associated with discernible cognitive impairment. Many subjects with LATE-NC have comorbid brain pathologies, often including amyloid-β plaques and tauopathy. Given that the 'oldest-old' are at greatest risk for LATE-NC, and subjects of advanced age constitute a rapidly growing demographic group in many countries, LATE has an expanding but under-recognized impact on public health. For these reasons, a working group was convened to develop diagnostic criteria for LATE, aiming both to stimulate research and to promote awareness of this pathway to dementia. We report consensus-based recommendations including guidelines for diagnosis and staging of LATE-NC. For routine autopsy workup of LATE-NC, an anatomically-based preliminary staging scheme is proposed with TDP-43 immunohistochemistry on tissue from three brain areas, reflecting a hierarchical pattern of brain involvement: amygdala, hippocampus, and middle frontal gyrus. LATE-NC appears to affect the medial temporal lobe structures preferentially, but other areas also are impacted. Neuroimaging studies demonstrated that subjects with LATE-NC also had atrophy in the medial temporal lobes, frontal cortex, and other brain regions. Genetic studies have thus far indicated five genes with risk alleles for LATE-NC: GRN, TMEM106B, ABCC9, KCNMB2, and APOE. The discovery of these genetic risk variants indicate that LATE shares pathogenetic mechanisms with both frontotemporal lobar degeneration and Alzheimer's disease, but also suggests disease-specific underlying mechanisms. Large gaps remain in our understanding of LATE. For advances in prevention, diagnosis, and treatment, there is an urgent need for research focused on LATE, including in vitro and animal models. An obstacle to clinical progress is lack of diagnostic tools, such as biofluid or neuroimaging biomarkers, for ante-mortem detection of LATE. Development of a disease biomarker would augment observational studies seeking to further define the risk factors, natural history, and clinical features of LATE, as well as eventual subject recruitment for targeted therapies in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Statistical analyses on data related to LATE from the Rush University community-based autopsy cohort depicting the results of pathway analyses. Data were analysed from research volunteers (total n = 1309) in two clinical‐pathological studies of ageing from Rush University as described previously (Power et al., 2018). In this sample, the mean age of death was 89.7 years [standard deviation (SD) 6.5 years, range 65–108 years]. These analyses incorporated age, density of amyloid-β neuritic amyloid plaques (to factor in ADNC), TDP-43 proteinopathy, hippocampal sclerosis pathology, and the endpoint of Alzheimer’s-type clinical dementia. The components of the pathway analyses most strongly associated with LATE-NC are shown in red. The numbers are path coefficients with standard error in parentheses (shown in purple). These numbers help to quantify the effects of individual pathways. For instance, the data are compatible with there being two pathways from TDP-43 proteinopathy to dementia, one direct pathway (TDP-43 proteinopathy→dementia) and the other indirect pathway that includes hippocampal sclerosis pathology (TDP-43 proteinopathy→hippocampal sclerosis→dementia): in the statistical model, the TDP-43 proteinopathy is independently associated with both hippocampal sclerosis pathology and clinical dementia status. Further, the data indicate that a subset of TDP-43 proteinopathy is ‘downstream’ of ADNC-type neuritic amyloid plaque pathology. In a practical sense, this means that brains with more neuritic amyloid plaques are more likely to have TDP-43 proteinopathy, with all other known factors being the same. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/9bc83b3adf7f42d5a250b59d9652e7a1/limbic-predominant-age-related-tdp-43-encephalopathy-late-consensus-working-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A consensus group, for example, has described hippocampal sclerosis associated with TDP-43 proteinopathy, as limbic-predominant age-related TDP-43 encephalopathy (LATE) dementia, usually found in people older than 80 years, progressing more slowly than Alzheimer's disease, detectable at post-mortem, often mimicking or comorbid with Alzheimer's disease.3”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“50–60% of Alzheimer’s-type dementia (dementia defined clinically as Alzheimer’s disease) is estimated to be attributable to these copathologies.40,42–45”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LATE is a recently described entity which affects older people and presents with an amnestic picture resembling Alzheimer's disease 178 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [178]
The cited source says what the claim attributes to it.
In the citing paper
“Limbic-predominant age-related TDP43 encephalopathy (LATE), defined approximately 3 years ago, is a condition in which typical TDP43 protein inclusions are present with or without coexisting hippocampal sclerosis.29”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The predominant neuropathological change in LATE is TDP-43 proteinopathy, which is associated with a clinical presentation of amnestic dementia that can mimic Alzheimer's dementia.”
From Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy (2020) · cites this paper as [20]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Self-citationBlessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · cited 1×
“LATE-NC is mostly seen in the oldest-old, whereas in early clinical-pathological correlation studies of dementia (Roth et al., 1966; Blessed et al., 1968), the research subjects had died in their early 70s.”
BackgroundAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This stratification will enable enrichment for subjects on the ADNC continuum (Sevigny et al., 2016) while excluding subjects likely to have high risk for LATE-NC (Botha et al., 2018).”
BackgroundMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Self-citationStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“seen at autopsy with every year of advanced old age (Braak et al., 2011; Nelson et al., 2011a, 2013; Brenowitz et al., 2014; Neltner et al., 2016).”
BackgroundPorta, M. (2026) · doi:10.1093/acref/9780197663639.001.0001 · Cited by 2,175
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citation
Research works printed but not linked: 3
- Kuslansky G, Verghese J, Dickson D, Katz M, Busche H, Lipton RB Hippocampal sclerosis: cognitive consequences and contribution to dementia. Neurology 2004; 62: A128– 9.
- Porta M. Dictionary of Epidemiology. 6th edn. New York: Oxford University Press; 2014.
- Thom M, Sisodiya S Epilepsy. In: Love S, Perry A, Ironside JW, Budka H, editors. Greenfield’s Neuropathology. New York: CRC Press; 2015 p. 683– 739.
Cited by
Items 901–1,000 of 1,004
A suggested shared aetiology of dementia - a colocalization study
Yu, X., Lophatananon, A., Mekli, K., Burns, A. S., Muir, K. R., & Guo, H. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.05.005 · Cited by 7
Rusina, R., Bajtošová, R., Cséfalvay, Z., Keller, J., Kavková, A., Kukal, J., & Matěj, R. (2022) · Behavioural Neurology · doi:10.1155/2022/6075511 · Cited by 7
Malotaux, V., Colmant, L., Quenon, L., Huyghe, L., Gérard, T., Dricot, L., Ivanoiu, A., Lhommel, R., & Hanseeuw, B. J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230696 · Cited by 7
Validation of a newly developed immunoassay for TDP-43 in human plasma
Matsuura, S., Tatebe, H., Higuchi, M., & Tokuda, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24672 · Cited by 7
Fuller‐Thomson, E., & Deng, Z. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190943 · Cited by 7
Alzheimer's disease: A need for personalized therapeutic approaches
Frenkel, D. (2020) · Drug Development Research · doi:10.1002/ddr.21652 · Cited by 7
Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine
Duce, J. A., Zhu, X., Jacobson, L. H., & Beart, P. M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14767 · Cited by 7
What to do with unusual TDP‐43 proteinopathy cases?
Nelson, P. T. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12745 · Cited by 7
Self-citationBaghel, M. S., Burns, G. D., Tsapatsis, M., Mallika, A. P., Cruz, A. L., Cao, T., Chen, X. K., Rosa, I. D. L., Marx, S. R., Ye, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.26.600814 · Cited by 7
Saunders, C., Rocha-Rangel, P., Desai, R., Quadri, Z., Lui, H., Hunt, J. B., Liang, H., Rogers, C. B., Nash, K. R., Tsoi, P. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.28.639952 · Cited by 7
Self-citationBrain microRNAs differentially expressed in age-related cerebral pathologies
Luo, T., Vattathil, S. M., Lori, A., Schneider, J. A., Bennett, D. A., Wingo, T. S., & Wingo, A. P. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.03.014 · Cited by 6
Self-citationLATE, Hippocampal Sclerosis, and Primary Age-related Tauopathy
Ramanan, V. K., & Graff‐Radford, J. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001499 · Cited by 6
Hemispheric asymmetry in neurodegenerative diseases
Cappa, S. F. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-15646-5.00009-9 · Cited by 6
Uchino, A., Hasegawa, K., Yagishita, S., Nagai, M., Ogino, M., Ogino, Y., Hatsuta, H., Murayama, S., & Saito, Y. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13148-3 · Cited by 6
Self-citationUltra‐fast MRI for dementia diagnosis and treatment eligibility: A prospective study
Rosa‐Grilo, M., Chughtai, H. R., Thomas, D. L., Alexander, D. C., Beament, M., Belder, C. R. S., Jäger, H. R., Lim, E., Magill, N., Mallon, D. H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70341 · Cited by 6
TDP ‐43 proteinopathies and neurodegeneration: insights from Caenorhabditis elegans models
Pir, G. J., Buddenkotte, J., Alam, M. A., Own, A. M., Eck, R. J., Kraemer, B. C., Mandelkow�, E., & Steinhoff, M. S. (2025) · FEBS Journal · doi:10.1111/febs.70239 · Cited by 6
Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study
Ono, D., Sekiya, H., Ghayal, N. B., Maier, A. R., Roemer, S. F., Uitti, R. J., Litvan, I., Josephs, K. A., Wszołek, Z. K., & Dickson, D. W. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13459-5 · Cited by 6
Self-citationNeuropathologic Changes in People With Essential Tremor With Dementia: A Postmortem Study
Wainman, E., Berry, D. S., Hernandez, N. C., Guy, T. O., Cosentino, S., Faust, P. L., & Louis, E. D. (2025) · Neurology · doi:10.1212/wnl.0000000000214310 · Cited by 8
Hogan, A. L., Kane, M. A., Chiu, P., Richter, G., Maurel, C., Wu, S., Scherer, N. M., Don, E. K., Lee, A., Blair, I. P., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02159-w · Cited by 6
Mapping multipathology via spatial omic integration
Palaganas, R. G., Sidiropoulos, D. N., Morris, M., & Stein-O’Brien, G. (2025) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2025.103398 · Cited by 6
Ngam, P. I., Anzai, Y., Brown, C. J. C., Frost, N. A., Sorweid, M. K., Thientunyakit, T., Minoshima, S., & Initiative, A. D. N. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270614 · Cited by 6
Caviedes, A., Cabral‐Miranda, F., Orellana, P., Hernández, H., Henriquez, F. A., González-Gómez, R., Pizarro, M., Migeot, J., Ochoa‐Rosales, C., Gonzalez‐Silva, C., et al. (2026) · Nature Aging · doi:10.1038/s43587-025-01061-3 · Cited by 6
A neurotoxic cryptic peptide arising from TDP-43-dependent cryptic splicing of PKN1
Yang, M., Wang, Q., Yan, R., Kang, D., Luo, W., Zhang, L., Liu, R., Wu, L., Gu, J., & Wang, X. (2026) · Nature Communications · doi:10.1038/s41467-026-68916-0 · Cited by 6
Groot, C., Calandri, I. L., Bader, I., Bocancea, D. I., de Bruin, H., Carrigan, M., Collij, L. E., Duits, F. H., Kamps, S., de Koning, L. A., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214810 · Cited by 6
Dodich, A., Crespi, C., Santi, G. C., Marcone, A., Iannaccone, S., Perani, D., Cappa, S. F., & Cerami, C. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617721000254 · Cited by 6
Criterios diagnósticos en la enfermedad demencial ¿Qué hay de nuevo?
Labos, E., Bavec, C. V., Cristalli, D. O., Deschle, F., Isaac, C. F., Dorman, G. S., Ollari, J., Rubiño, V., & Russo, M. J. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i160.460 · Cited by 6
Cognitive Decline and Other Late-Stage Neurologic Complications in Cockayne Syndrome
Rajamani, G., Stafki, S. A., Daugherty, A. L., Mantyh, W. G., Littel, H. R., Bruels, C. C., Pacak, C. A., Robbins, P. D., Niedernhofer, L. J., Abiona, A., et al. (2024) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200309 · Cited by 6
Ingrassia, L., Boluda, S., Potier, M., Haïk, S., Jiménez, G., Kar, A., Racoceanu, D., Delatour, B., & Stimmer, L. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae048 · Cited by 6
Focused review: Clinico-neuropathological aspects of late onset epilepsies
Rácz, Á., Galvis-Montes, D. S., Borger, V., Becker, A. J., & Pitsch, J. (2024) · Seizure · doi:10.1016/j.seizure.2024.06.015 · Cited by 6
George, G., Ajayan, A., Varkey, J., PANDEY, N. K., Chen, J., & Langen, R. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107660 · Cited by 6
Liou, J., Li, J., Berardinelli, J., Jin, H., Santini, T., Noh, J., Farhat, N., Wu, M., Aizenstein, H. J., Mettenburg, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.083741 · Cited by 6
LATE: Nicht jede Demenz ist Alzheimer – Diskussion einer neuen Krankheitsentität am Fallbeispiel
Göerß, D., Kilimann, I., Dyrba, M., Nitsch, S., Krause, B. J., & Teipel, S. J. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00922-z · Cited by 6
Multiple aetiologies of the progressive dysexecutive syndrome and the importance of biomarkers
Jones, D. T. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa127 · Cited by 6
Gene‐ and age‐informed screening for preclinical Alzheimer's disease trials
Spencer, B. E., Digma, L. A., Jennings, R. G., Brewer, J. B., & Initiative, A. D. N. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12207 · Cited by 6
Klotz, S., & Gelpí, E. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-021-00848-4 · Cited by 6
Fernandez-Romero, R., & Spica, D. M. (2021) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001020 · Cited by 6
New Models for Managing Longevity Risk: Public-Private Partnerships
Mitchell, O. S. (2022) · doi:10.1093/oso/9780192859808.001.0001 · Cited by 6
Orlando, A., Sharrett, A. R., Schneider, A. L. C., Gottesman, R. F., Knopman, D. S., Rawlings, A. M., Mosley, T. H., Jack, C. R., Wong, D. F., Pike, J. R., et al. (2022) · Neuroepidemiology · doi:10.1159/000524731 · Cited by 6
Self-citationBrain MRI Biomarkers to Predict Cognitive Decline in Older People with Alzheimer’s Disease
Zhu, L.-Y., Shi, L., Luo, Y., Leung, J. C. S., & Kwok, T. C. Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215189 · Cited by 6
Fang, X., Wu, F., & Jiang, C. (2023) · BMC Neurology · doi:10.1186/s12883-023-03224-4 · Cited by 6
Ortega‐Cruz, D., Bress, K. S., Gazula, H., Rábano, A., Iglesias, J. E., & Strange, B. A. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13695 · Cited by 6
Shigemoto, Y., Sone, D., Ota, M., Maikusa, N., Ogawa, M., Okita, K., Takano, H., Kato, K., Kimura, Y., Morimoto, E., et al. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0552-3 · Cited by 6
Krolak‐Salmon, P. (2020) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/s1627-4830(20)30195-1 · Cited by 6
TDP-43 Aggregate Seeding Impairs Autoregulation and Causes TDP-43 DysfunctionPreprint
Mamede, L. D., Hu, M., Titus, A. R., Vaquer‐Alicea, J., French, R. L., Diamond, M. I., Miller, T. M., & Ayala, Y. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.11.637743 · Cited by 6
Neurodegeneration risk variants promote lysosomal TMEM106B fibril accumulationPreprint
Replogle, J. M., Marks, J. D., Fernandez, M. G., Yuan, H., Yu, D., Winters, E., Jawahar, V. M., Deshmukh, R., Sutanto, R., Kowal, I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.26.714634 · Cited by 6
Self-citationAn, J., Gopalakrishnan, L., Ortega, V., Saul, J., Kadali, R., & Bowser, R. P. (2024) · Biosensors · doi:10.3390/bios14120578 · Cited by 5
Richter, N., Breidenbach, L., Schmieschek, M. H. T., Heiss, W., Fink, G. R., & Onur, O. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251324080 · Cited by 5
Alzheimer mimicry: LATE and PART
Bogdanović, N., Smailović, U., & Jelić, V. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02916-0 · Cited by 5
Myristoylation of TMEM106B by NMT1/2 regulates TMEM106B trafficking and turnover
Lacrampe, A., Hou, D., Perez, I. G., Gong, B., Franco-Hernandez, N., Yee, A., Chen, W., Young-Chapon, M. A., Lin, H., & Hu, F. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110322 · Cited by 5
del Val, G., Gauye, F., Audrain, M., Menant, S., Ratnam, M., Chevalier, E., Ollier, R., Bhatia, D., Seredenina, T. S., Afroz, T., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.026 · Cited by 5
Circular RNAs from the MAPT and TARDBP genes: Novel players in neurodegeneration?
Bagheri, N., Margvelani, G., Chiang, T.-W., Nelson, P. T., Chuang, T., & Stamm, S. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106019 · Cited by 5
Self-citationSajjadi, S. A., Khan, Z., El‐Khoury, A., Bubbico, G., Akhlaghipour, G., Corrada, M. M., Kawas, C. H., & Paganini‐Hill, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70450 · Cited by 5
Self-citationTDP-43–immunity–microbiota axis in amyotrophic lateral sclerosis: A potential pathogenic mechanism
Abbassi, Y., Fink, D., Cei, F., Niccolai, E., & Amedei, A. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00440 · Cited by 5
Neuropsychiatric symptom subtypes and dementia‐associated neuropathologic change
Cholerton, B., Beecham, G. W., Reitz, C., Vito, A. N. D., Cuccaro, M. L., Kukull, W. A., Montine, T. J., & Huey, E. D. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70622 · Cited by 5
Self-citationThe National Alzheimer's Coordinating Center (NACC) 1999–2025: Personal history and recollections
Kukull, W. A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70836 · Cited by 5
Self-citationAre current etiological theories of Alzheimer’s disease falsifiable? An epistemological assessment
Costa, T., & Liloia, D. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1708234 · Cited by 5
Richardson, T. E., Kandoi, S., Almeida, F., Rohde, S. K., Marx, G. A., Canbeldek, L., Hiya, S., Maldonado‐Díaz, C., Samanamud, J. L., Clare, K. M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01904-6 · Cited by 5
Nucleolar aggregation of key neuropathological proteins in the postmortem neurodegenerative brain
Lourenco, G. F., Torres-Pacheco, M. E., Fu, Y., Li, H., McCann, H., Shepherd, C. E., Kril, J. J., & Halliday, G. M. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02968-2 · Cited by 5
Self-citationNeuropathologic Profiles and Associated Cognitive Trajectories in Community-Living Older Adults
Yu, L., Wang, T., Du, L., Bennett, D. A. A., Schneider, J. A., & Boyle, P. A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.54354 · Cited by 5
Self-citationSpinal Cord Tau and Protein Copathologies Associated With Chronic Traumatic Encephalopathy
Tanaka, H., Black, L. E., Forrest, S. L., Danics, K., Sadia, N., Khodadadi, M., Tator, C., Smith, D. H., Tartaglia, M. C., Stewart, W., et al. (2026) · JAMA Neurology · doi:10.1001/jamaneurol.2025.5421 · Cited by 5
Mamede, L. D., Hu, M., Vaquer‐Alicea, J., Titus, A. R., dos Passos, P. M., Lantelme, E., French, R. L., Kirschner, P. A., Diamond, M. I., Miller, T. M., et al. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003662 · Cited by 5
The potential of low-field MRI for global dementia care
Evans, T. E., Harper, J. R., Salehi, A., WEBB, A. G., Cole, J. H., Correa, A., Adams, H. H. H., Cash, D. M., & Jones, D. K. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01199-7 · Cited by 5
Medial temporal lobe tau–neurodegeneration mismatch from structural imaging and plasma biomarkers
Lyu, X., Mundada, N. S., Brown, C., Sadeghpour, N., McGrew, E., Xie, L., Li, Y., Wuestefeld, A., Duong, M. T., Cook, P. A., et al. (2026) · Brain · doi:10.1093/brain/awag105 · Cited by 5
CCCDTD5: research diagnostic criteria for Alzheimer's Disease
Gauthier, S. G., Chertkow, H. M., Theriault, J., Chayer, C., Ménard, M., Lacombe, G., Rosa‐Neto, P., & Ismail, Z. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12036 · Cited by 5
Journe‐Mallet, I., Gouju, J., Etcharry‐Bouyx, F., Chauviré, V., Guillet, V., Scherer‐Gagou, C., Prundean, A., Godard, S., Lecluse, A., Cassereau, J., et al. (2022) · Brain Pathology · doi:10.1111/bpa.13138 · Cited by 5
Ottaviani, S., & Monacelli, F. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231071 · Cited by 5
Chronic traumatic encephalopathy neuropathologic change in former Australian rugby players
Shepherd, C. E., McCann, H., McLean, C. A., Iverson, G. L., & Gardner, A. J. (2024) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12972 · Cited by 5
Design principles to tailor Hsp104 therapeutics
Lin, J., Carman, P. J., Gambogi, C. W., Kendsersky, N. M., Chuang, E., Gates, S. N., Yokom, A. L., Rizo, A. N., Southworth, D. R., & Shorter, J. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115005 · Cited by 5
White matter hyperintensities and TDP‐43 pathology in Alzheimer's disease
Carlos, A. F., Weigand, S. D., Pham, N. T. T., Petersen, R. C., Jack, C. R., Dickson, D. W., Whitwell, J. L., & Josephs, K. A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14516 · Cited by 5
Self-citationYoussef, H., Gatto, R. G., Pham, N. T. T., Jones, D. T., Petersen, R. C., Machulda, M. M., Whitwell, J. L., & Josephs, K. A. (2025) · Neuropathology · doi:10.1111/neup.70000 · Cited by 6
Melikyan, Z. A., Al‐Darsani, Z., Colcord, K. A., Paganini‐Hill, A., Jiang, L., Bukhari, S. A., Montine, T. J., Kawas, C. H., & Corrada, M. M. (2025) · Neurology · doi:10.1212/wnl.0000000000213948 · Cited by 5
Self-citationPrimary age-related tauopathy in a Chinese cohort
Wang, X., Zhang, L., Lü, H., Wu, J., Liang, H., Liu, C., Tao, Q., Wu, Z., & Zhu, K. (2020) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900262 · Cited by 5
Pallidal degenerations and related disorders: an update
Jellinger, K. A. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02392-2 · Cited by 5
Multz, R. A., Spencer, C., Matos, A., Ajroud, K., Zamudio, C., Bigio, E. H., Mao, Q., Medeiros, R. A., Ahrendsen, J. T., Castellani, R. J., et al. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac114 · Cited by 5
Self-citationMaioli, H., Mittenzwei, R., Shofer, J. B., Scherpelz, K. P., Marshall, D. A., Nolan, A., Nelson, P. T., Keene, C. D., & Latimer, C. S. (2023) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlad035 · Cited by 5
Self-citationLi, K., Luo, X., Zeng, Q., Liu, X., Li, J., Zhong, S., Zhang, X., Xu, X., Wang, S., Hong, H., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106354 · Cited by 5
Neuropathologic changes at age 90+ related to sleep duration 19 to 40 years earlier: The 90+ Study
Melikyan, Z. A., Kawas, C. H., Paganini‐Hill, A., Jiang, L., Bukhari, S. A., Montine, T. J., Mander, B. A., & Corrada, M. M. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13798 · Cited by 5
Self-citationStehouwer, J. S., Huang, G., Guarino, D. S., Debnath, M. L., Polu, A., Geib, S. J., Lopresti, B. J., Ikonomović, M. D., Mason, N. S., Mach, R. H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02988 · Cited by 5
Current clinical approaches in neurodegenerative diseases
Gago, M. F., Machado, Á. S., & Rocha, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00004-0 · Cited by 5
da Silva, E. T. C., da Silva, A. F., da Costa, S. R. R., Bezerra, P. L., Lourenço, A. H. A., & Pereira, N. E. G. (2021) · Research Society and Development · doi:10.33448/rsd-v10i1.11831 · Cited by 5
Park, S., Oh, M., Kim, J. H., Lee, J., Yoon, Y. W., & Roh, J. H. (2021) · Brain Sciences · doi:10.3390/brainsci11040465 · Cited by 5
Role of Triggers on the Structural and Functional Facets of TAR DNA-binding Protein 43
Camilus, N. S., Arias, C. Q., & Martić, S. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.11.027 · Cited by 5
Koga, S., Murakami, A., Soto‐Beasley, A. I., Walton, R. L., Baker, M., Castanedes‐Casey, M., Josephs, K. A., Ross, O. A., & Dickson, D. W. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01611-z · Cited by 5
Self-citationSalaikumaran, M. R., & Gopal, P. P. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00659 · Cited by 5
Lalive, H. M., Griffa, A., Carlier, S., Nasuti, M., Noto, T. D., Maréchal, B., Rouaud, O., & Allali, G. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240026 · Cited by 5
Asken, B. M., Thomas, K. R., Lee, A. K. W., Davis, J. D., Malloy, P. F., Salloway, S., & Initiative, A. D. N. (2019) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617719001346 · Cited by 5
Novel monoclonal antibodies targeting the RRM2 domain of human TDP-43 protein
Trejo‐Lopez, J. A., Sorrentino, Z. A., Riffe, C. J., Lloyd, G. M., Labuzan, S. A., Dickson, D. W., Yachnis, A. T., Prokop, S., & Giasson, B. I. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135353 · Cited by 5
Self-citationRábano, A., Márquez, C. G., Juste, R. A., Geijó, M., & Calero, M. (2021) · Biomolecules · doi:10.3390/biom11030413 · Cited by 5
Pais, M. V., Loureiro, J. C., do Vale, V. S., Radanovic, M., Talib, L. L., Stella, F., & Forlenza, O. V. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210144 · Cited by 5
AD and its comorbidities: An obstacle to develop a clinically efficient treatment?
Baker, J., & Schott, J. M. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.001 · Cited by 5
Koyano, S., Yagishita, S., Tada, M., Doi, H., Uchihara, T., & Tanaka, F. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac032 · Cited by 5
Deafferentation of Olfactory Bulb in Subjects Dying with COVID-19Preprint
Tremblay, C., Beach, T. G., Intorcia, A. J., Walker, J. E., Arce, R. A., Sue, L. I., Nelson, C. M., Borja, C. I., Suszczewicz, K. E., Cline, M. P., et al. (2021) · medRxiv · doi:10.1101/2021.12.21.21268119 · Cited by 5
Mallika, A. P., Yu, J., Sitzman, O., Baghel, M. S., Renganathan, S., Sinha, I. R., Melnikova, T., Ling, J. P., & Wong, P. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.14.670400 · Cited by 5
Serio, M. A., Dethloff, D. R., Curry, G. C., Beesley, M. L., Shekoohi, S., & Kaye, A. D. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03337-x · Cited by 4
Zaikos, T. D., Guo, H., Barrett, A., Dastgheyb, R. M., Rubin, L. H., Troncoso, J. C., & Morris, M. (2025) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaf102 · Cited by 4
TGF-β signaling as an organismal proteostasis regulator
Zhu, H., Zhang, Q., Tian, Y., & Cohen, E. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.07.008 · Cited by 4
Abnormal Amyloid-β Duration, Tau, and Neurodegeneration in Cranial Images
Stephenson, H. G., Langhough, R. E., Jonaitis, E. M., Du, L., Hulle, C. V., Chin, N. A., Okonkwo, O. C., Carlsson, C. M., Asthana, S., Christian, B., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.31093 · Cited by 4
Digital seed amplification assay for TDP‐43 aggregate quantification in CSF
Borberg, E., Swank, Z., Gilboa, T., Shearer, L. A. W., Melkonian, A. V., Rolando, J. C., Walt, D. R., & Stern, A. M. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71272 · Cited by 4
CSF pTDP-43 across the Alzheimer's spectrum: Links to amyloid, APOE and vasculopathy
Rafiee, Z., Pocevičiūtė, D., Santiago, J., Mahmoud, R., Janelidze, S., Hansson, O., & Wennström, M. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107193 · Cited by 4
Elucidation of Molecular Mechanisms of Lipid-Altered Cytotoxicity of TDP-43 Fibrils
Purvinsh, Y., Matveyenka, M., & Kurouski, D. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00934 · Cited by 4
Metadata
- Authors
- Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., Coyle-Gilchrist, I. T. S., Chui, H. C., Fardo, D. W., Flanagan, M. E., Halliday, G., Hokkanen, S. R. K., Hunter, S., Jicha, G. A., Katsumata, Y., Kawas, C. H., Keene, C. D., Kovacs, G. G., Kukull, W. A., Levey, A. I., Makkinejad, N., Montine, T. J., Murayama, S., Murray, M. E., Nag, S., Rissman, R. A., Seeley, W. W., Sperling, R. A., White III, C. L., Yu, L., & Schneider, J. A.
- Affiliations
- University of Kentucky (US)
- Mayo Clinic in Florida (US)
- University of Pennsylvania (US)
- Mayo Clinic (US)
- Rush University Medical Center (US)
- Uppsala University (SE)
- Newcastle University (GB)
- University of Cambridge (GB)
- University of Southern California (US)
- University of Minnesota (US)
- The University of Sydney (AU)
- University of California, Irvine (US)
- University of Washington (US)
- Institute of Neurology Medical University of Vienna, Vienna, Austria
- Emory University (US)
- Illinois Institute of Technology (US)
- Stanford University (US)
- Tokyo Metropolitan Institute of Gerontology (JP)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Harvard University (US)
- University of Texas Southwestern Medical Center, Dallas, TX, USA
- Corresponding author
- Nelson, Peter T
- ORCID
- Nelson, Peter T
- Dickson, Dennis W
- Trojanowski, John Q
- Jack, Clifford R
- Boyle, Patricia A
- Arfanakis, Konstantinos
- Rademakers, Rosa
- Alafuzoff, Irina
- Attems, Johannes
- Brayne, Carol
- Coyle-Gilchrist, Ian T S
- Chui, Helena C
- Fardo, David W
- Flanagan, Margaret E
- Halliday, Glenda
- Hokkanen, Suvi R K
- Hunter, Sally
- Jicha, Gregory A
- Katsumata, Yuriko
- Kawas, Claudia H
- Keene, C Dirk
- Kukull, Walter A
- Levey, Allan I
- Makkinejad, Nazanin
- Montine, Thomas J
- Murayama, Shigeo
- Murray, Melissa E
- Nag, Sukriti
- Rissman, Robert A
- Seeley, William W
- Sperling, Reisa A
- Yu, Lei
- Schneider, Julie A
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-30
- Volume
- 142
- Issue
- 6
- Pages
- 1503-1527
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6536849
- OpenAlex
- W2943828894
- Cited by
- 1,547
- References
- 276
- Citations by year
- 2026: 206 · 2025: 240 · 2024: 211 · 2023: 214 · 2022: 213 · 2021: 193 · 2020: 198 · 2019: 66
- FWCI
- 113.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UKnowledge (University of Kentucky) (submittedVersion, cc-by-nc)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Apollo
- Funders
- NIA
- NACC
- NIH (U01 AG016976)
- National Health and Medical Research Council
- NHMRC (1132524, 1095127, 1037746)
- Senior Principal Research Fellowship (1079679)
- National Institutes of Health (P01 AG003949, R01 AG037491, P50 AG016574, R01 AG054449, P30 AG028303, P30 AG012300, P30 AG049638, P30 AG010124, P30 AG010161, P50 AG047366, P50 AG025688, P50 AG005131, R37 AG011378, R01 AG041851, R01 AG042210, R01 AG017917, R01 AG034374, UF1 AG053983, UF1 AG057707)
- NIHR (534906, NF-SI-0616–10090)
- National Institute for Health Research
- NHS
- Department of Health and Social Care
- Addenbrooke’s Charitable Trust
- Paul G. Allen Family Foundation and Alzheimer’s Research
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- limbic-predominant age-related TDP-43 encephalopathy, TDP-43 proteinopathy, hippocampal sclerosis, diagnostic criteria, neuropathological staging, amygdala, medial temporal lobe atrophy, genetic risk variants, gene regulatory networks, TMEM106B, ABCC9, apolipoprotein E, Alzheimer's disease, frontotemporal lobar degeneration
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Brain Diseases, Female, Humans, Male, Middle Aged, Retrospective Studies, Frontotemporal Lobar Degeneration, TDP-43 Proteinopathies, Frontotemporal Dementia, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.